| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
13.92(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $265 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oyler John |
Chief Executive Officer |
• • – |
2021-07-21 |
4 |
AS |
$304.93 |
$4,707,356 |
D/D |
(15,260) |
0 |
|
13% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-21 |
4 |
AS |
$24.58 |
$292,466 |
D/D |
(11,900) |
5,639,665 |
|
13% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-20 |
4 |
AS |
$316.85 |
$5,097,413 |
D/D |
(15,995) |
0 |
|
11% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-20 |
4 |
AS |
$24.61 |
$681,642 |
D/D |
(27,700) |
5,849,945 |
|
11% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-07-15 |
4 |
AS |
$330.53 |
$6,980,771 |
D/D |
(21,000) |
0 |
|
10% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-07-15 |
4 |
OE |
$119.96 |
$3,085,002 |
D/D |
21,000 |
21,000 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-08 |
4 |
AS |
$310.64 |
$5,058,016 |
D/D |
(15,881) |
0 |
|
18% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-08 |
4 |
AS |
$24.24 |
$1,243,717 |
D/D |
(51,300) |
6,085,580 |
|
18% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-07 |
4 |
AS |
$325.23 |
$97,570 |
D/D |
(300) |
0 |
|
17% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-07 |
4 |
AS |
$310.38 |
$8,115,775 |
D/D |
(25,746) |
300 |
|
17% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-07 |
4 |
AS |
$25.14 |
$1,023,247 |
D/D |
(40,700) |
6,343,333 |
|
17% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-06 |
4 |
AS |
$321.72 |
$4,249,567 |
D/D |
(13,075) |
0 |
|
14% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-07-06 |
4 |
AS |
$25.42 |
$1,126,048 |
D/D |
(44,300) |
6,722,631 |
|
14% |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2021-07-06 |
4 |
AS |
$321.46 |
$3,313,927 |
D/D |
(10,180) |
0 |
|
14% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2021-07-01 |
4 |
AS |
$342.68 |
$1,687,852 |
D/D |
(4,848) |
0 |
|
0% |
|
| Wang Julia Aijun |
Chief Financial Officer |
• – – |
2021-07-01 |
4 |
S |
$349.06 |
$107,512 |
D/D |
(308) |
0 |
|
-0% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-06-29 |
4 |
AS |
$347.63 |
$528,198 |
D/D |
(1,500) |
0 |
|
3% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-06-29 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-06-28 |
4 |
AS |
$365.00 |
$155,125 |
D/D |
(425) |
0 |
|
4% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2021-06-28 |
4 |
S |
$362.48 |
$164,930 |
D/D |
(455) |
0 |
|
-4% |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2021-06-28 |
4 |
S |
$365.00 |
$162,790 |
D/D |
(446) |
0 |
|
-4% |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2021-06-18 |
4 |
S |
$325.89 |
$158,383 |
D/D |
(486) |
0 |
|
-19% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-06-18 |
4 |
S |
$325.66 |
$152,733 |
D/D |
(469) |
0 |
|
-19% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2021-06-18 |
4 |
S |
$331.15 |
$265,583 |
D/D |
(802) |
0 |
|
-19% |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2021-06-18 |
4 |
S |
$330.93 |
$382,551 |
D/D |
(1,156) |
0 |
|
-19% |
|
241 Records found
|
|
Page 2 of 10 |
|
|
5.02 (3.38%) 
